

The Association between Androgen Receptor Expression and Some Pathological Characteristics in Patients with Breast Cancer

Abstract

Context: Breast cancer is the most current malignancy in women all around the world. Considering the presence of the androgen receptor as a possible prognostic marker, attention has been given to its association with other molecular markers such as estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (Her 2)/neu, and clinicopathological characteristics and the target of cancer therapy. **Aims:** This study aimed to assess the level of androgen receptor (AR) and its association with other clinicopathological factors in patients with breast cancer. **Settings and Design:** Samples from 100 breast cancer patients were studied to evaluate the expression of AR using immunohistochemistry. **Subjects and Methods:** The association of AR was evaluated with ER, PR, and Her2 levels; age; tumor size; tumor grade; histological grade; nuclear grade; vascular invasion; perineural invasion; and lymph node involvement. The correlation between the expression of AR and other factors was assessed using *t*, Mann–Whitney, and Chi-square tests using SPSS. **Results:** Among 100 patients, 50 (50%) cases were AR positive. There was a significant correlation between AR expression and triple-negative breast cancer and the expressions of ER, PR, and Her2. However, there was no significant association between AR expression and other clinicopathological markers such as age, tumor size, type of tumor, and histological grade. **Conclusion:** Owing to the expanded expression of AR in 50% of patients with breast cancer in this study as well as the significant association between AR expression and triple-negative breast carcinoma, AR ER, PR, and Her 2, could be considered as a promising prognostic factor.

Keywords: Androgen receptor, breast cancer, human epidermal growth factor receptor 2, triple-negative

Introduction

Breast cancer is a common malignancy with the incidence of one million cases a year.^[1,2] It is the second common leading reason behind death following lung cancer in females aged 20–59 years.^[3,4] It is also the leading cause of 16% of all cancers in women and 18.2% of deaths worldwide.^[5] It is a probability of 1:8 for a woman to develop breast cancer until the age of 90 years.^[6] The incidence of breast cancer increased in developed countries, which seems to be due to the lifestyle and different regimens in women.^[5] However, because of the early recognition and favorable treatment of breast carcinoma, the incidence is decreasing.

The diagnosis of breast cancer is done through breast examination, routine mammography, fine-needle aspiration

biopsy, and core-needle biopsy.^[7] Aspiration cytology is a simple, fast, precise, cheap, and nonaggressive method, which should be evaluated by an expert cytopathologist.^[8,9] Furthermore, aspiration cytology seems to be the best way to diagnose and assess breast lesions.^[1,10,11]

Breast cancer has several risk factors including age, first relatives with breast cancer, atypical hyperplasia, race, estrogen therapy, radiation, cancer in the cross breast and endometriosis, geographical distribution, food regimen, obesity, sports, and lactation.^[11,12] The prognosis of breast carcinoma is related to several characteristics such as patient's age, early detection, pregnancy, necrosis, tumor size, BRCA1, Her2, p53, estrogen receptor (ER) and progesterone receptor (PR) expression, tumoral emboli to lymphatics, microvessel density, and metastasis to lymph node under the armpit. Several prognostic factors, such as the status of tumor markers at the time

**Mahdokht Azizi,
Seyed Hamid
Madani,
Babak Izadi,
Sedigheh Khazaei¹,
Elahe Saleh²,
Mitra Tarlan¹**

Molecular Pathology Research Center, Imam Reza Hospital, Kermanshah University of Medical Sciences, ¹Clinical Research Development Center, Imam Reza Hospital, Kermanshah University of Medical Sciences, Kermanshah, ²Department of Epidemiology and Biostatistics, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran

Submitted: 17-Jul-2020

Revised: 29-Sep-2020

Accepted: 23-Nov-2020

Published: 19-Feb-2021

Address for correspondence:

*Prof. Seyed Hamid Madani,
Molecular Pathology Research Center, Emam Reza Hospital, Zakaria Razi Bol, Kermanshah University of Medical Science, Kermanshah, Iran.*

E-mail: shmmadani@yahoo.com

Access this article online

Website: www.cci-j-online.org

DOI: 10.4103/ccij.cci_j_103_20

Quick Response Code:



How to cite this article: Azizi M, Madani SH, Izadi B, Khazaei S, Saleh E, Tarlan M. The association between androgen receptor expression and some pathological characteristics in patients with breast cancer. *Clin Cancer Investig J* 2021;10:15-21.

This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

For reprints contact: WKHLRPMedknow_reprints@wolterskluwer.com

of diagnosis, are considered to determine the severity of the disease and choose a treatment modality. These factors can help assess the potential of invasion and the effectiveness of cotreatments such as chemotherapy.^[13,14] Detection of ER, PR, and Her2 as a predictor and prognostic markers in breast cancer can result in advance of targeted therapies such as using tamoxifen, aromatase inhibitors, and trastuzumab. In this line, the detection of novel promising markers such as androgen receptor (AR) seems to be useful in the progress of innovative therapies in breast cancer.^[15]

AR is steroid hormone receptors (ligand-activated nuclear transcription factor) that have a similar structure to receptors of progesterone, estrogen, thyroid hormone, glucocorticoid, retinoid, and mineralocorticoid.^[16] Three functional parts of AR include the DNA-binding domain and the ligand-binding domain and N-terminal transcription factor.^[17] Similar to testosterone and dihydrotestosterone, the activity of androgen is regulated by AR as a member of the nuclear receptor family of steroid hormone. Owing to the expression of AR in a large number of cells and tissues, it plays several functions such as development and protection of reproduction, immune, hematopoietic, muscular skeleton, and cardiovascular systems. The role of androgen is mediated by the pathway dependent on interaction with DNA to regulate transcription of target genes and independent on DNA interaction for the onset of cellular events.^[18,19] The signaling pathways from AR seem to be involved in tumors of prostate, bladder, breast, liver, and kidney.^[20] It has been shown that AR is expressed in more than 70% of breast carcinoma, and the AR positivity is considerably high compared with other markers such as ER and PR.^[21-23] Nuclear ARs have different expressions from 80% to 85% in early breast cancer and 60%–75% in metastatic cases. In triple-negative breast cancer (TNBC), the expression of AR is about 53%. Recent clinical studies have shown that some antiandrogenic therapies, including enzalutamide and abiraterone acetate alone and together with other medicines, are useful in treating breast cancer, especially those with focal invasion, or with metastasis, and also in TNBC.^[24] The expression of AR is measured using immunohistochemistry. Specimens with 10% or more nuclear staining are considered as AR positive.^[25,26]

AR and its ligand androgens may play a vital role in breast cancer, but the clinical impact of the expression of AR was not well identified. This study aimed to evaluate the level of AR in samples of breast carcinoma and its association with other clinicopathological factors in patients with breast cancer.

Subjects and Methods

Materials

AR, PR, ER, Her2, liquid 3, 3'-diaminobenzidine tetrahydrochloride (DAB)+ Substrate Chromogen System, Envision, Biotin Blocking System, Dual Link System

DakoK3468, Denmark); Target Retrieval Solution (DAKO S2367, Denmark); Hematoxylin (Panreac, Spain); Primary and secondary antibody (Master Diagnosis, Spain); Hydrogen peroxide, Methyl alcohol, Entelan glue, Ethyl alcohol 99.6%, NaCl, ethylenediaminetetraacetic acid and Tris (hydroxymethyl) aminomethane (All from Merk, Germany); Ethyl alcohol 96–70% and Xylene (Shiminab, Iran); Pepsin (Sigma, Germany). During the test, all test apparatuses were standard and calibrated.

Patients' samples

Retrospectively, 100 formalin-fixed paraffin-embedded tissues were selected from the patients who had been referred to Imam Reza Hospital, Kermanshah city, Iran. Excision less than total mastectomy includes specimens designated excision, segmental resection, lumpectomy, quadrantectomy, and segmental or partial mastectomy with axillary content. Slides were ready from paraffin blocks of the specimens and stained with the quality standard hematoxylin and eosin (H and E) method. All the specimens were analyzed, and two freelance pathologists confirmed the original diagnoses. The sample size was calculated by the available sampling method and subsequent formula:

$$n = \frac{Z_{1-\frac{\alpha}{2}}^2 P(1-P)}{d^2}$$

In which n = Sample size; $Z_{1-\frac{\alpha}{2}}$ = Confidence interval, P = Estimated proportion, and d = Desired precision.

$$\text{Therefore, } n = \frac{1.96^2 0.8(1-0.8)}{0.08^2} \approx 97$$

The inclusion criteria for the samples were selecting tissue samples of primary breast carcinoma. The exclusion criteria were patients with metastatic breast carcinoma and men with breast cancer. The Ethics Committee of Kermanshah University of Medical Sciences approved the study (code number: KUMS. REC.1394.47) in 2014.

Hematoxylin and eosin staining

4- μ m sections of paraffin-embedded tissues were stained with H and E method. The subsequent step is to incubate the glass slides containing tissue sections (70°C for 2 h). Then, the slides were washed in several jars full of xylene, a series of ethanol solutions, hematoxylin, lithium carbonate, and eosin. Two pathologists independently assessed the stained sections.

Immunohistochemistry

Immunohistological staining was carried out on formalin-fixed paraffin-embedded tissue sections using antibodies against AR, PR, ER, and human epidermal growth factor receptor 2 (Her 2). as described previously.^[27] For this, 4- μ m tissue sections were deparaffinized for 24 h at 60°C–65°C. Afterward, the slides were rehydrated for approximately 45 min in xylene and a graded sequence of ethanol solutions. The slides were immersed in the jar

containing Tris buffer (pH = 9) and warmed for 20 min in the autoclave at 121°C followed by washing in PBS solution to retrieve antigens. Then, the slides were soaked for 15 min in a solution of 3% hydrogen peroxide in methanol, washed with phosphate-buffered saline (PBS), to quench peroxidase intracellular activity. Biotin was then applied to improve staining specificity.

After washing with PBS, the slides were incubated by primary and secondary antibodies at 60 and 45 min, respectively, in a humid and dark place at room temperature. The slides were washed in PBS and stained with the substrate–chromogen solution known as DAB for 5 min. The counterstaining was carried out for 30–60 s with hematoxylin then lithium carbonate (5 min) and washed in water. The stained slides were immersed in a graded ethanol series and then xylene to tissue transparency and dehydration. Then, the slides were mounted under a microscope to the test. Negative controls were applied to antibody diluents to remove the primary antibody.

AR-positive samples were stained in more than 10% of tumoral cells; otherwise, they would be classified in the negative group [Figure 1]. If more than 1% of tumor cells had nuclear staining of PR, they were considered positive PR cells. Her2/neu is diagnosed with membrane staining based on complete or incomplete staining and tumor cell staining intensity. Score 0 demonstrates no membrane staining or <10% of the tumor cells, score 1⁺ reveals mild membrane incomplete staining in more than 10% of the tumor cells, score 2⁺ presents a weak or moderate complete membrane staining in more than 10% of the tumor cells, and score 3⁺ shows a robust and complete membrane staining in more than 30% of the tumor cells.

Statistical analysis

Using (SPSS Inc., Chicago, IL, USA), the data were analyzed using *t*, Mann–Whitney, and Chi-square measures; the association between the expression of AR and other variables was tested. All differences were considered statistically significant at the level of $P < 0.05$.




Figure 1: (a) Androgen receptor-positive breast cancer. Stained androgen receptor in breast cancer tissue (brown color) and (b) androgen receptor-negative breast cancer. There is no brown color staining in androgen receptor-negative breast cancer tissue

Results

All the participants in this sample are people with early breast cancer. In this study, all the patients were women with early breast carcinoma. One hundred patients in this study had invasive ductal carcinoma, and one case had invasive lobular carcinoma. Table 1 summarizes the clinicopathological characteristics of the patients. The minimum age of the patients was 19 years, and the maximum period was 78 years, with the mean age of 49 years. The tumor size range was 5–100 mm, an average of 31 mm. Fifty percent of the patients were AR positive, and 50% were AR negative. No significant association was found between the expression of AR and age ($P = 0.343$). According to the Mann–Whitney and Chi-square tests, there was no significant association between the tumor type, tumor size, microscopic grade, and nuclear grade of the tumor with the level of AR expression ($P = 0.568, 0.109, 0.854, \text{ and } 0.216$, respectively). Furthermore, the Chi-square test indicated that there was no vascular invasion, neural invasion, and lymph node involvement ($P = 0.509, 0.229, \text{ and } 0.838$, respectively). Evaluation of the expression of AR in TNBC indicated that 29.42% of TNBC were AR positive, and there was a significant association between the level of AR and TNBC [$P = 0.003$, Table 2]. Furthermore, the results of Chi-square test showed that there was a significant relationship between the level of AR expression and the level of ER ($P = 0.001$), PR ($P = 0.027$), and Her 2 ($P = 0.029$). AR expression was observed in 56% (28 of 50) of PR-positive and 64% (32 of 50) of ER-positive cancers and 24% (12 of 50) of Her 2-positive cancer patients. AR expression was observed in 44% (22 of 50) of PR-negative and 36% (18 of 50) of ER-negative and 76% (38 of 50) of Her2-positive cancer patients.

Discussion

Breast cancer has a worldwide distribution and is the most common malignancy as one out of eight women is affected by the disease.^[1,2] However, given that several novel therapeutic strategies and diagnostic methods have been developed to detect tumors in early stages (<2 cm), the incidence of death from breast carcinoma has decreased in recent decades.^[1,2] Breast cancer has been suggested to be a common and heterogeneous disorder. In this line, some clinical factors are considered to be important in the determination of prognosis and even treatment, including age, lymph node involvement, tumor size, tumor type, grade, and neural invasion.^[28] There is also a wide range of growth and development of breast cancer cells, which affects the clinical period of the disease and is the most critical factor in prognosis.^[29]

It is well established that androgen promotes the growth of prostate cancer and estrogen promotes the growth of breast cancer. The effectiveness of androgen for breast cancer therapy, however, has not been well characterized.

Table 1: Clinicopathological characteristics of 100 patients with breast cancer

Clinicopathological characteristics	n
Age (years)	
<40	24
40-50	29
50-60	28
>60	19
Tumor type	
Ductal	97
Lobular	1
Mixed	2
AR	
Positive	50
Negative	50
TNBC	
Positive	24
Negative	10
Microscopic grade	
1	24
2	60
3	16
Nuclear grade	
1	9
2	63
3	28
Vascular invasion	
Negative	29
Positive	71
Perineural invasion	
Negative	54
Positive	46
Lymph node involvement	
Negative	61
Positive	39
Tumor size (mm)	
<20	41
20-50	40
>50	19
ER	
Negative	52
Positive	48
PR	
Negative	52
Positive	48
Her 2	
Negative	84
Positive	16
Her 2 score	
0	22
1	13
2	49
3	16

TNBC: Triple-negative breast cancer, ER: Estrogen receptor, PR: Progesterone receptor, AR: Androgen receptor

Conflict findings have been found in research on the role of androgen in breast cancer.^[29,30]

Fujita demonstrated that, *in vitro*, androgen had an inhibitory effect on breast cancer at normal plasma levels.^[31]

Our results showed that half of the studied patients were AR positive. McNamara *et al.* showed that AR was diagnosed in 85% of early breast cancer patients and 75% of metastatic cases.^[32] In a study by Collins *et al.*, the expression of AR in 2171 invasive breast cancers and 246 ductal carcinomas *in situ* was 77% and 86%, respectively.^[33] Hu *et al.* showed that among 1467 breast cancer cases, 78.7% were AR positive. Of the 1164 ER-positive cases, 88% were AR positive, which was associated with a considerable decrease in death.^[34] In 2010, showed that among 652 breast cancer patients with the mean age of 49 years, 72.9% expressed AR, which was higher than the expression of ER and PR.^[34] In a cohort study by Anand *et al.* in India in 2017, the study of AR expression among 116 patients showed no association of AR with age and size of tumors that were in line with our research.^[35] Mohammadizadeh *et al.* showed that 64.3% of breast cancer cases were AR positive that were among the younger population with an increased level of tumors and smaller size (<2 cm). However, the grade and stage of tumor in cases with negative AR were more than patients with positive AR without a substantial difference between the two groups.^[36]

Two previous studies have suggested the association of AR-positive status with older age at the time of diagnosis.^[37,38] On the contrary, the research in Iran stated that patients with AR-positive tumors were younger than patients with AR negative. Most research, however, has declared that age does not seem to impact AR positivity.^[39,40]

The present research showed no association between tumor size and AR status. Other studies, however, have indicated that the smaller tumors are more likely to be AR positive.^[38,40] Payandeh *et al.* reported that there was no statistical correlation between AR and the type of tumor.^[41] In another study, the expression of AR was 73.7% in different types of ductal carcinoma. The higher levels of AR positive were observed in carcinomas of tubular (100%), apocrine (100%), lobular (83.3%), and papillary (81%), whereas the higher levels of AR negative were found in plastic, medullary, and mucinous types.^[42] It has been reported that AR is continually expressed in several types of breast cancer, such as apocrine and lobular carcinoma, whereas it is minimally expressed in some other types, including mucinous. However, these studies have been conducted in a small population.^[37,43] The involvement of lymph nodes is one of the important predictive and prognostic factors for outcomes of patients suffering from breast cancer.^[44,45]

Table 2: The association between clinicopathological characteristics and androgen receptor expression

Variable	AR expression		P
	Positive	Negative	
Age			
<40	10	14	0.343
40-50	15	14	
50-60	14	14	
>60	11	8	
Tumor size (cm)			
<2	23	18	0.109
2<<=5	21	19	
>5	6	13	
Vascular invasion			
Present	34	37	0.509
Absent	16	13	
Tumoral type			
Ductal	49	48	0.568
lobular	0	1	
Lobular and ductal	1	1	
Microscopic grade			
1	12	12	0.854
2	29	31	
3	9	7	
Nuclear grade			
1	2	7	0.216
2	33	30	
3	15	13	
Lymph node involvement			
Present	19	20	0.838
Absent	31	30	
Perineural invasion			
Present	20	26	0.229
Absent	30	24	
TNBC	10	24	0.003
ER			
Positive	32	34	0.001
Negative	18	32	
PR			
Positive	28	17	0.027
Negative	33	28	
Her 2			
Positive	12	4	0.029
Negative	46	38	

TNBC: Triple-negative breast cancer, ER: Estrogen receptor, PR: Progesterone receptor, AR: Androgen receptor

We found no statistically significant association between AR expression and involvement of the lymph nodes. Two studies have also verified the lack of significant relationship between expression of AR and involving lymph nodes.^[46,47] Other studies showed a significant association between AR expression and lymph node involvement.^[48-53] The intranuclear receptors, ER and PR, and the membrane receptor Her2 regulate breast cancer growth. ER-positive

and PR-positive breast cancers are known to be less aggressive and as sensitive to endocrine care as well. Her2-positive tumors have been identified as aggressive and responsive to trastuzumab and anthracycline therapy.

We found a significant correlation between the expression of AR, ER, PR, and Her 2. Other studies reported that AR was significantly expressed in ER positive and PR positive.^[47,54]

Secreto *et al.* evaluated ER and AR and they found that 90% of ER-positive tumors were AR positive and also 55% of ER-negative tumors were AR positive.^[55]

In another study, 89% of ER-positive breast cancers were AR positive, although only 49% of ER-negative cancers were AR positive.^[48]

In this study, we noted that 66% of ER-positive patients and 36% of ER-negative patients expressed AR. We concluded, as with other research, that ER-positive tumors express AR- more than ER-negative tumors.^[56]

There were 24% of AR-positive cancers that were HER2 positive and 76% of AR-positive cancers were HER2 negative. We found a significant correlation between HER 2 and AR. Other studies reported that there was no significant association between AR and HER2.^[47,54] Naderi *et al.* reported a cross action between AR and HER2 in androgen-sensitive tumors.^[57]

AR has been found to be expressed in some proportion of TNBC and may play a role in this subgroup as a prognostic marker and a therapeutic target.^[23,58,59]

In two recent review articles, the AR expression levels in TNBC ranged from 0% to 53%.^[37,51] In this study, 29.42% of TNBC were AR positive, and there was a significant association between the level of AR and TNBC ($P = 0.003$).

Conclusion

Given the well-known prognostic functions of ER, PR, and Her2/neu, detecting the novel, reliable markers is required for effective breast cancer diagnosis and evaluating therapeutic targets. AR could be used as a clinical target due to the presence of AR in 50% of breast cancer patients in this study and its strong interaction with TNBC.

Acknowledgments

The authors would like to thank the Clinical Research Development Center of Imam Reza Hospital for Consulting Services. In addition, we thank Maryam Jafari for the technical support and Molecular Pathology Research Center, Imam Reza hospital, for their cooperation. This research was provided as a part of the requirements for residency of pathology Mahdokht Azizi, in the School of Medicine, Kermanshah University of Medical Sciences, Kermanshah, Iran.

Financial support and sponsorship

The study was financially supported by the Kermanshah University of Medical Sciences (grant 95246).

Conflicts of interest

There are no conflicts of interest.

References

- Rosai J. Rosai and Ackerman's Surgical Pathology. Amsterdam: Elsevier Health Sciences; 2011.
- Weidner N, Cote RJ, Suster S, Weiss LM. Modern Surgical Pathology. Amsterdam: Elsevier Health Sciences; 2009.
- Kamani F, Fathi A. Hormonal receptors evaluation in breast cancer. J Isfahan Med Schl 2011;29.
- Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, *et al.* Cancer statistics, 2008. CA Cancer J Clin 2008;58:71-96.
- Nordqvist C. Breast cancer: Causes, symptoms and treatments. Med News Today Med Lexicon Intl 2016;5: [in press](#).
- Walters KA, Simanainen U, Handelsman DJ. Molecular insights into androgen actions in male and female reproductive function from androgen receptor knockout models. Hum Reprod Update 2010;16:543-58.
- Nazário AC, Facina G, Filassi JR. Breast cancer: News in diagnosis and treatment. Rev Assoc Med Bras (1992) 2015;61:543-52.
- Gray W, McKee G. Inflammatory Conditions and Benign Breast Lesions. Diagnostic Cytopathology. 2nd ed. London, United Kingdom: Churchill Livingstone; 2003. p. 271-2.
- Briffod M, Hacène K, Le Doussal V. Immunohistochemistry on cell blocks from fine-needle cytopunctures of primary breast carcinomas and lymph node metastases. Mod Pathol 2000;13:841-50.
- Carter D. Interpretation of Breast Biopsies. Philadelphia, Pennsylvania, United States: Lippincott Williams & Wilkins; 2003.
- Ries L, Eisner M, Kosary C, Hankey B, Miller B, Clegg L. Surveillance, Epidemiology, and End Results (SEER) Program SEER* Stat Data base: Incidence-SEER 9 Regs Public-Use, Nov 2004 Sub (1973-2002). National Cancer Institute, Division of Cancer Control and Population Sciences, Surveillance Research Program, Cancer Statistics Branch. Released April 2005, based on the November 2004 Submission; 2008.
- Gail MH, Anderson WF, Garcia-Closas M, Sherman ME. Absolute Risk Models for Subtypes of Breast Cancer. Oxford, England: Oxford University Press; 2007.
- Mylonas I, Makovitzky J, Jeschke U, Briese V, Friese K, Gerber B. Expression of Her2/neu, steroid receptors (ER and PR), Ki67 and p53 in invasive mammary ductal carcinoma associated with ductal carcinoma *in situ* (DCIS) versus invasive breast cancer alone. Anticancer Res 2005;25:1719-23.
- Hashemi EM, Akbari ME, Najafi M, Haghghat SH, Kaviani A. Role of tumor markers in breast cancer recurrence. Guilan Univ Med Sci J 2006;15:23-8.
- Safarpour D, Tavassoli FA. A targetable androgen receptor-positive breast cancer subtype hidden among the triple-negative cancers. Arch Pathol Lab Med 2015;139:612-7.
- Peters AA, Buchanan G, Ricciardelli C, Bianco-Miotto T, Centenera MM, Harris JM, *et al.* Androgen receptor inhibits estrogen receptor- α activity and is prognostic in breast cancer. Cancer Res 2009;69:6131-40.
- MacLean HE, Warne GL, Zajac JD. Localization of functional domains in the androgen receptor. J Steroid Biochem Mol Biol 1997;62:233-42.
- Davey RA, Grossmann M. Androgen receptor structure, function and biology: From bench to bedside. Clin Biochem Rev 2016;37:3-15.
- Yu Q, Niu Y, Liu N, Zhang J, Liu T, Zhang R, *et al.* Expression of androgen receptor in breast cancer and its significance as a prognostic factor. Ann Oncol 2010;22:1288-94.
- Somboonporn W, Davis SR, National Health and Medical Research Council. Testosterone effects on the breast: Implications for testosterone therapy for women. Endocr Rev 2004;25:374-88.
- Moinfar F, Okcu M, Tsybrovskyy O, Regitnig P, Lax SF, Weybora W, *et al.* Androgen receptors frequently are expressed in breast carcinomas. Cancer 2003;98:703-11.
- Kuennen-Boumeester V, Van der Kwast TH, Claassen CC, Look MP, Liem GS, Klijn JG, *et al.* The clinical significance of androgen receptors in breast cancer and their relation to histological and cell biological parameters. Eur J Cancer 1996;32A: 1560-5.
- Nahleh Z. Androgen receptor as a target for the treatment of hormone receptor-negative breast cancer: An uncharted territory. Future Oncol 2008;4:15-21.
- Héquet D, Mzoughi S, Rouzier R, Guccione E. Androgen receptors in breast cancer: Expression, value and therapeutic prospects. Bull Cancer 2017;104:363-9.
- Mishra AK, Agrawal U, Negi S, Bansal A, Mohil R, Chintamani C, *et al.* Expression of androgen receptor in breast cancer & its correlation with other steroid receptors & growth factors. Indian J Med Res 2012;135:843.
- Zakaria F, El-Mashad N, Mohamed D. Androgen receptor expression as a prognostic and predictive marker in triple-negative breast cancer patients. Alexandria J Med 2016;52:131-40.
- Danaei S, Madani SH, Khazaei S, Izadi B, Saleh E, Sajadimajd S. The survey of Her2/neu expression and its correlation with some pathological factors in urothelial bladder tumors. Iran Red Crescent Med J 2018;20:e58494.
- Cotran R, Kumar V, Robbins S. Pathologic Basis of Disease. Philadelphia, PA: Saunders. Elsevier; 2010.
- Labrie F, Luu-The V, Labrie C, Bélanger A, Simard J, Lin SX, *et al.* Endocrine and intracrine sources of androgens in women: Inhibition of breast cancer and other roles of androgens and their precursor dehydroepiandrosterone. Endocr Rev 2003;24:152-82.
- Wong YC, Xie B. The role of androgens in mammary carcinogenesis. Ital J Anat Embryol 2001;106:111-25.
- Fujita H. Inhibition and stimulation of proliferation by testosterone in human breast cancer cell MCF-7. Ann Rep Tokyo Metr Inst PH 2004;55:335-8.
- McNamara KM, Moore NL, Hickey TE, Sasano H, Tilley WD. Complexities of androgen receptor signalling in breast cancer. Endocr Relat Cancer 2014;21:T161-81.
- Collins LC, Cole KS, Marotti JD, Hu R, Schnitt SJ, Tamimi RM. Androgen receptor expression in breast cancer in relation to molecular phenotype: Results from the nurses' health study. Mod Pathol 2011;24:924-31.
- Hu R, Dawood S, Holmes MD, Collins LC, Schnitt SJ, Cole K, *et al.* Androgen receptor expression and breast cancer survival in postmenopausal women. Clin Cancer Res 2011;17:1867-74.
- Anand A, Singh KR, Kumar S, Husain N, Kushwaha JK, Sonkar AA. Androgen receptor expression in an Indian breast cancer cohort with relation to molecular subtypes and response to neoadjuvant chemotherapy-a prospective clinical study. Breast Care 2017;12:160-4.
- Mohammadzadeh F, Sajadieh S, Sajjadieh H, Kasaei Z.

- Androgen receptor expression and its relationship with clinicopathological parameters in an Iranian population with invasive breast carcinoma. *Adv Biomed Res* 2014;3:132.
37. Cho LC, Hsu YH. Expression of androgen, estrogen and progesterone receptors in mucinous carcinoma of the breast. *Kaohsiung J Med Sci* 2008;24:227-32.
 38. Ghannam A, Galal S, Ellity M. Expression of androgen receptors in primary breast cancer. *Europ Soc Med Oncol* 2016;21:488-92.
 39. Mrklíć I, Pogorelić Z, Capkun V, Tomić S. Expression of androgen receptors in triple negative breast carcinomas. *Acta Histochem* 2013;115:344-8.
 40. Pistelli M, Caramanti M, Biscotti T, Santinelli A, Pagliacci A, De Lisa M, *et al.* Androgen receptor expression in early triple-negative breast cancer: Clinical significance and prognostic associations. *Cancers (Basel)* 2014;6:1351-62.
 41. Payandeh M, Shazad B, Madani S, Ramezani M, Sadeghi M. Androgen receptor expression and its correlation with other risk factors in triple negative breast cancers: A report from Western Iran. *Asian Pac J Cancer Prev* 2016;17:3321-4.
 42. Park S, Koo J, Park HS, Kim JH, Choi SY, Lee JH, *et al.* Expression of androgen receptors in primary breast cancer. *Ann Oncol* 2010;21:488-92.
 43. Shim HS, Jung WH, Kim H, Park K, Cho NH. Expression of androgen receptors and inhibin/activin α and β A subunits in breast apocrine lesions. *APMIS* 2006;114:352-8.
 44. McGhan LJ, McCullough AE, Protheroe CA, Dueck AC, Lee JJ, Nunez-Nateras R, *et al.* Androgen receptor-positive triple negative breast cancer: A unique breast cancer subtype. *Ann Surg Oncol* 2014;21:361-7.
 45. McNamara KM, Yoda T, Takagi K, Miki Y, Suzuki T, Sasano H. Androgen receptor in triple negative breast cancer. *J Steroid Biochem Mol Biol* 2013;133:66-76.
 46. Choi JE, Kang SH, Lee SJ, Bae YK. Androgen receptor expression predicts decreased survival in early stage triple-negative breast cancer. *Ann Surg Oncol* 2015;22:82-9.
 47. Park S, Koo J, Park H, Kim JH, Choi SY, Lee J, *et al.* Expression of androgen receptors in primary breast cancer. *Ann Oncol* 2010;21:488-92.
 48. Agoff SN, Swanson PE, Linden H, Hawes SE, Lawton TJ. Androgen receptor expression in estrogen receptor-negative breast cancer. Immunohistochemical, clinical, and prognostic associations. *Am J Clin Pathol* 2003;120:725-31.
 49. Bièche I, Parfait B, Tozlu S, Lidereau R, Vidaud M. Quantitation of androgen receptor gene expression in sporadic breast tumors by real-time RT-PCR: Evidence that MYC is an AR-regulated gene. *Carcinogenesis* 2001;22:1521-6.
 50. Isola JJ. Immunohistochemical demonstration of androgen receptor in breast cancer and its relationship to other prognostic factors. *J Pathol* 1993;170:31-5.
 51. Moifar F, Okcu M, Tsybrovskyy O, Regitnig P, Lax SF, Weybora W, *et al.* Androgen receptors frequently are expressed in breast carcinomas: Potential relevance to new therapeutic strategies. *Cancer* 2003;98:703-11.
 52. Riva C, Dainese E, Caprara G, Rocca PC, Massarelli G, Tot T, *et al.* Immunohistochemical study of androgen receptors in breast carcinoma. Evidence of their frequent expression in lobular carcinoma. *Virchows Arch* 2005;447:695-700.
 53. Søreide JA, Lea OA, Varhaug JE, Skarstein A, Kvinnsland S. Androgen receptors in operable breast cancer: Relation to other steroid hormone receptors, correlations to prognostic factors and predictive value for effect of adjuvant tamoxifen treatment. *Eur J Surg Oncol* 1992;18:112-8.
 54. Ogawa Y, Hai E, Matsumoto K, Ikeda K, Tokunaga S, Nagahara H, *et al.* Androgen receptor expression in breast cancer: Relationship with clinicopathological factors and biomarkers. *Int J Clin Oncol* 2008;13:431-5.
 55. Secreto G, Venturelli E, Meneghini E, Carcangiu ML, Paolini B, Agresti R, *et al.* Androgen receptors and serum testosterone levels identify different subsets of postmenopausal breast cancers. *BMC Cancer* 2012;12:599.
 56. Vojdani R, Geramizadeh B, Mohammadkarimi V, Talei A, Rezvani A, Dorniani G, *et al.* A survey of the relationship between serum testosterone level and expressions of androgen, progesterone and estrogen receptors and HER2 in Iranian women with breast cancer. *Middle East J Cancer* 2015;6:143-50.
 57. Naderi A, Hughes-Davies L. A functionally significant cross-talk between androgen receptor and ErbB2 pathways in estrogen receptor negative breast cancer. *Neoplasia* 2008;10:542-8.
 58. Moe RE, Anderson BO. Androgens and androgen receptors: A clinically neglected sector in breast cancer biology. *J Surg Oncol* 2007;95:437-9.
 59. Rakha EA, El-Sayed ME, Green AR, Lee AH, Robertson JF, Ellis IO. Prognostic markers in triple-negative breast cancer. *Cancer* 2007;109:25-32.